LSD therapy

What LSD is

LSD is a semi-synthetic ergoline-class compound acting primarily as a partial agonist at the 5-HT_2A receptor — the same receptor target as psilocybin, though with different binding kinetics and a substantially longer duration. A typical oral clinical dose of 100–200 µg produces onset within 30–90 minutes, a plateau over 4–6 hours, and a return to baseline at roughly 10–12 hours.

Historically, LSD was the psychedelic most actively studied in psychiatric research between the mid-1950s and the late 1960s, with thousands of published reports covering alcoholism, anxiety, and end-of-life distress. Schedule I classification in 1970 effectively ended that era. The current renaissance focuses primarily on one pharmaceutical program.

MM120 — the Phase 3 LSD program

Mind Medicine (MindMed) is developing MM120 (lysergide D-tartrate) as an orally disintegrating tablet (ODT) intended for single-dose administration in-office. The program is the only Phase 3 psychedelic development effort for LSD worldwide.

Phase 2b (MMED008)

The 198-patient dose-ranging study (25, 50, 100, 200 µg vs placebo) in generalized anxiety disorder produced the foundational efficacy signal:³

• The 100 µg dose produced the largest effect on the Hamilton Anxiety Rating Scale (HAM-A) at Week 4 and Week 12.
• At Week 12, the 100 µg cohort showed a 65% clinical response rate and 48% clinical remission rate — sustained from a single administration.
• Adverse events were generally mild to moderate, transient, and concentrated on the dosing day.

On the strength of those results, the FDA granted MM120 Breakthrough Therapy Designation in March 2024 and MindMed held its End-of-Phase 2 meeting shortly after.¹

Phase 3 (Voyage, Panorama, Emerge)

Panorama’s additional 50-microgram arm is a deliberate design response to the blinding concerns the FDA raised in its MDMA CRL — by comparing two active doses and a placebo, the study aims to separate subjective "perceptual" effects from genuine therapeutic effect.²

Why LSD rather than psilocybin for anxiety?

MindMed’s chief medical officer has publicly argued that LSD has several differentiators relative to ketamine and SSRIs as GAD treatments: a single-dose paradigm (versus daily SSRI dosing), a rapid onset (versus weeks for SSRIs), and a large effect size (Phase 2b effect sizes of 0.7–0.8 versus roughly 0.3 for SSRIs). These comparisons are pre-Phase 3 and will be tested directly when Voyage and Panorama read out.

Other indications (historical and small-sample)

• End-of-life anxiety. Gasser et al. (2014) randomized 12 patients with life-threatening illness to active-dose LSD (200 µg) or placebo-dose (20 µg) plus psychotherapy. Active-dose patients showed significant reductions in anxiety that persisted at 12 months.⁴ Small trial but an important early signal.
• Alcohol use disorder. Krebs & Johansen (2012) meta-analysis of six 1960s–70s trials reported a significant short-term benefit. Not replicated with modern methodology.
• Cluster headache. Small open-label work at Yale with non-hallucinogenic LSD analogs is in very early stages.

Microdosing — what the evidence actually shows

Microdosing — taking ~10–20 µg of LSD (roughly 1/10 of a macrodose) on a schedule such as every third day — is a major internet phenomenon. The self-report literature is full of positive claims around focus, mood, and creativity. The controlled literature is much more sobering.

The most-cited controlled trial is Szigeti et al. (2021) in eLife, which used a "self-blinding" citizen-science protocol with 191 regular microdosers. Over four weeks, all psychological benefits could be attributed to expectancy effects — both the active and placebo arms improved similarly.⁵ Subsequent controlled work (Aday et al., Bershad et al.) has generally reached the same conclusion: the measurable acute effects of microdoses are small, and durable cognitive or mood benefits are not reliably distinguishable from placebo.

Safety & side effects

Longer-term considerations:

• Persistent perceptual changes (HPPD). Rare in clinical-use contexts but documented; risk appears concentrated in heavy recreational users.
• Psychosis risk. Classical contraindication is personal or family history of primary psychotic or bipolar disorder.
• Cardiovascular. 5-HT_2B agonism is a theoretical concern for cardiac valvulopathy with chronic exposure; single-dose clinical paradigms are not expected to carry this risk.
• Addiction potential. Very low — LSD does not produce compulsive self-administration in any controlled model.

Legal status

LSD is Schedule I in the United States — no accepted medical use, research requires FDA IND and DEA Schedule I registration. MM120 holds Breakthrough Therapy Designation, which affects review speed and FDA engagement but does not change the current scheduling. An approved MM120 NDA would ultimately require DEA rescheduling.

Internationally, LSD is controlled in most jurisdictions. Switzerland’s limited "compassionate use" scheme has authorized a small number of individual LSD-assisted psychotherapy cases since 2014.

How to actually access it

Clinical trials. MM120 Voyage, Panorama, and Emerge are the primary open-to-enrollment pathways in the US and Europe. Check ClinicalTrials.gov for current site listings. Trial participants must meet GAD or MDD diagnostic criteria and typically must be medication-stable or willing to taper serotonergic medications under supervision.

Compassionate-use programs. Switzerland is the only country with an established physician-led pathway outside of trials.

Not available: there is no legal retreat model for LSD comparable to ayahuasca retreats, and LSD is not covered under Oregon’s or Colorado’s state-legal psilocybin frameworks.

Preparation & integration

The long duration of LSD means a therapeutic session is a half-day commitment; preparation sessions focus on set-and-setting and intention-setting, and integration sessions in the following week(s) help patients work with insights. This follows the general psychedelic integration model.